Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model.

[1]  J. Weiss,et al.  Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. , 2011, Journal of the American College of Cardiology.

[2]  David A. Morrow,et al.  Relationship Between Nonsustained Ventricular Tachycardia After Non–ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death: Observations From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36 (MERLIN , 2010, Circulation.

[3]  T. Nieminen,et al.  T-Wave Alternans as a Therapeutic Marker for Antiarrhythmic Agents , 2010, Journal of cardiovascular pharmacology.

[4]  R. Kloner,et al.  Ranolazine: an anti-anginal drug with further therapeutic potential , 2010, Expert review of cardiovascular therapy.

[5]  R. Kloner,et al.  Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. , 2009, American Journal of Physiology. Heart and Circulatory Physiology.

[6]  M. Cutler,et al.  Explaining the clinical manifestations of T wave alternans in patients at risk for sudden cardiac death. , 2009, Heart rhythm.

[7]  Kapil Kumar,et al.  Basis for sudden cardiac death prediction by T-wave alternans from an integrative physiology perspective. , 2009, Heart rhythm.

[8]  Takanori Ikeda,et al.  Time-domain T-wave alternans measured from Holter electrocardiograms predicts cardiac mortality in patients with left ventricular dysfunction: a prospective study. , 2009, Heart rhythm.

[9]  Kapil Kumar,et al.  Effect of Ranolazine on Ventricular Vulnerability and Defibrillation Threshold in the Intact Porcine Heart , 2008, Journal of cardiovascular electrophysiology.

[10]  R. Kloner,et al.  The Antianginal Agent, Ranolazine, Reduces Myocardial Infarct Size but Does Not Alter Anatomic No-Reflow or Regional Myocardial Blood Flow in Ischemia/Reperfusion in the Rabbit , 2008, Journal of cardiovascular pharmacology and therapeutics.

[11]  Ranolozine‐Induced Suppression of Ventricular Tachycardia in a Patient with Nonischemic Cardiomyopathy: A Case Report , 2008, Pacing and clinical electrophysiology : PACE.

[12]  Heikki Huikuri,et al.  T-wave alternans predicts mortality in a population undergoing a clinically indicated exercise test. , 2007, European heart journal.

[13]  P. Picton,et al.  Endocardial and epicardial repolarization alternans in human cardiomyopathy: evidence for spatiotemporal heterogeneity and correlation with body surface T-wave alternans. , 2007, Journal of the American College of Cardiology.

[14]  P. Light,et al.  Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. , 2006, Journal of molecular and cellular cardiology.

[15]  R. Kloner,et al.  Improved Left Ventricular Function and Reduced Necrosis after Myocardial Ischemia/Reperfusion in Rabbits Treated with Ranolazine, an Inhibitor of the Late Sodium Channel , 2006, Journal of Pharmacology and Experimental Therapeutics.

[16]  J. Shryock,et al.  Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine , 2006, Heart.

[17]  A. Garfinkel,et al.  From Pulsus to Pulseless: The Saga of Cardiac Alternans , 2006, Circulation research.

[18]  Hani N Sabbah,et al.  Ranolazine Improves Abnormal Repolarization and Contraction in Left Ventricular Myocytes of Dogs with Heart Failure by Inhibiting Late Sodium Current , 2006, Journal of cardiovascular electrophysiology.

[19]  Andrew C. Zygmunt,et al.  Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.

[20]  R. Verrier,et al.  Tracking cardiac electrical instability by computing interlead heterogeneity of T-wave morphology. , 2003, Journal of applied physiology.

[21]  Shien-Fong Lin,et al.  Spatial heterogeneity of action potential alternans during global ischemia in the rabbit heart. , 2003, American journal of physiology. Heart and circulatory physiology.

[22]  R. Verrier,et al.  Modified moving average analysis of T-wave alternans to predict ventricular fibrillation with high accuracy. , 2002, Journal of applied physiology.

[23]  Shien-Fong Lin,et al.  Spatial Heterogeneity of Calcium Transient Alternans During the Early Phase of Myocardial Ischemia in the Blood-Perfused Rabbit Heart , 2001, Circulation.

[24]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[25]  R. Verrier,et al.  Potent antifibrillatory effect of combined blockade of calcium channels and 5-HT2 receptors with nexopamil during myocardial ischemia and reperfusion in dogs: comparison to diltiazem. , 1996, Journal of cardiovascular pharmacology.

[26]  S. S. Hull,et al.  K+ Channel Blockade in the Prevention of Ventricular Fibrillation in Dogs with Acute Ischemia and Enhanced Sympathetic Activity , 1995, Journal of cardiovascular pharmacology.

[27]  R. Verrier,et al.  Quantification of ischaemia induced vulnerability by precordial T wave alternans analysis in dog and human. , 1994, Cardiovascular research.

[28]  S Yasui,et al.  Significance of discordant ST alternans in ventricular fibrillation. , 1990, Circulation.

[29]  D. Sheridan,et al.  Effects of sotalol on arrhythmias and electrophysiology during myocardial ischaemia and reperfusion. , 1984, Cardiovascular research.

[30]  D. Harrison,et al.  The Effects of Diltiazem and Reduced Serum Ionized Calcium on Ischemic Ventricular Fibrillation in the Dog , 1982, Circulation research.

[31]  J. Spear,et al.  Ventricular fibrillation threshold; its physiological and pharmacological importance. , 1975, Archives of internal medicine.

[32]  L. Maclean,et al.  Ventricular fibrillation threshold. , 1961, The American journal of physiology.